Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2001 Feb 22

PMID 11181372

Citations 58

Authors

R Petraitiene

V Petraitis

A H Groll

T Sein

S Piscitelli

M Candelario

N Avila

J Bacher

T J Walsh

Affiliations

Soon will be listed here.

Abstract

The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of body weight per os; itraconazole (ITC) at 2, 6, and 20 mg/kg per os; or amphotericin B (AMB) at 1 mg/kg intravenously. Rabbits treated with POC showed a significant improvement in survival and significant reductions in pulmonary infarct scores, total lung weights, numbers of pulmonary CFU per gram, numbers of computerized-tomography-monitored pulmonary lesions, and levels of galactomannan antigenemia. AMB and POC had comparable therapeutic efficacies by all parameters. By comparison, animals treated with ITC had no significant changes in outcome variables in comparison to those of untreated controls (UC). Rabbits receiving prophylactic POC at all dosages showed a significant reduction in infarct scores, total lung weights, and organism clearance from lung tissue in comparison to results for UC (P < 0.01). There was dosage-dependent microbiological clearance of A. fumigatus from lung tissue in response to POC. Serum creatinine levels were greater (P < 0.01) in AMB-treated animals than in UC and POC- or ITC-treated rabbits. There was no elevation of serum hepatic transaminase levels in POC- or ITC-treated rabbits. The pharmacokinetics of POC and ITC in plasma demonstrated dose dependency after multiple dosing. The 2-, 6-, and 20-mg/kg dosages of POC maintained plasma drug levels above the MICs for the entire 24-h dosing interval. In summary, POC at > or =6 mg/kg/day per os generated sustained concentrations in plasma of > or =1 microg/ml that were as effective in the treatment and prevention of invasive pulmonary aspergillosis as AMB at 1 mg/kg/day and more effective than cyclodextrin ITC at > or =6 mg/kg/day per os in persistently neutropenic rabbits.

Citing Articles

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.

Maertens J, Slavin M, Hoenigl M, Thompson 3rd G, Richardson M, Lass-Florl C J Antimicrob Chemother. 2024; 79(8):1786-1793.

PMID: 39084680 PMC: 11334067. DOI: 10.1093/jac/dkae158.

Utilization of nanotechnology and experimental design in the development and optimization of a posaconazole‒calendula oil nanoemulgel for the treatment of mouth disorders.

Alissa M, Hjazi A, Abusalim G, Aloraini G, Alghamdi S, Alharthi N Front Pharmacol. 2024; 15:1347551.

PMID: 38434704 PMC: 10905964. DOI: 10.3389/fphar.2024.1347551.

Long-Term Kinetics of Serum Galactomannan during Treatment of Complicated Invasive Pulmonary Aspergillosis.

Tragiannidis A, Linke C, Correa-Martinez C, Herbruggen H, Schaumburg F, Groll A J Fungi (Basel). 2023; 9(2).

PMID: 36836274 PMC: 9965572. DOI: 10.3390/jof9020157.

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.

Thompson 3rd G, Boulware D, Bahr N, Clancy C, Harrison T, Kauffman C Open Forum Infect Dis. 2022; 9(6):ofac112.

PMID: 35611348 PMC: 9124589. DOI: 10.1093/ofid/ofac112.

Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.

Gastine S, Hope W, Hempel G, Petraitiene R, Petraitis V, Mickiene D Antimicrob Agents Chemother. 2020; 65(2).

PMID: 33168606 PMC: 7848991. DOI: 10.1128/AAC.01574-20.

References

Pannuti C, Gingrich R, Pfaller M, Kao C, Wenzel R . Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer. 1992; 69(11):2653-62. DOI: 10.1002/1097-0142(19920601)69:11<2653::aid-cncr2820691106>3.0.co;2-8. View

Anaissie E . Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992; 14 Suppl 1:S43-53. DOI: 10.1093/clinids/14.supplement_1.s43. View

Allende M, Lee J, Francis P, Garrett K, Dollenberg H, Berenguer J . Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 1994; 38(3):518-22. PMC: 284491. DOI: 10.1128/AAC.38.3.518. View

Berenguer J, Ali N, Allende M, Lee J, Garrett K, Battaglia S . Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994; 38(6):1303-8. PMC: 188202. DOI: 10.1128/AAC.38.6.1303. View

De Bock R . Epidemiology of invasive fungal infections in bone marrow transplantation. EORTC Invasive Fungal Infections Cooperative Group. Bone Marrow Transplant. 1994; 14 Suppl 5:S1-2. View

Stynen D, Goris A, Sarfati J, Latge J . A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol. 1995; 33(2):497-500. PMC: 227977. DOI: 10.1128/jcm.33.2.497-500.1995. View

Walsh T, Garrett K, Feurerstein E, Girton M, Allende M, Bacher J . Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother. 1995; 39(5):1065-9. PMC: 162684. DOI: 10.1128/AAC.39.5.1065. View

Verweij P, Stynen D, Rijs A, De Pauw B, Hoogkamp-Korstanje J, Meis J . Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol. 1995; 33(7):1912-4. PMC: 228297. DOI: 10.1128/jcm.33.7.1912-1914.1995. View

Sugar A, Liu X . In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother. 1996; 40(5):1314-6. PMC: 163319. DOI: 10.1128/AAC.40.5.1314. View

10.

Walsh T, Hiemenz J, Anaissie E . Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996; 10(2):365-400. DOI: 10.1016/s0891-5520(05)70303-2. View

11.

Perfect J, Cox G, Dodge R, Schell W . In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996; 40(8):1910-3. PMC: 163438. DOI: 10.1128/AAC.40.8.1910. View

12.

Rohrlich P, Sarfati J, Mariani P, Duval M, Carol A, Saint-Martin C . Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J. 1996; 15(3):232-7. DOI: 10.1097/00006454-199603000-00011. View

13.

Espinel-Ingroff A, Bartlett M, Bowden R, Chin N, Cooper Jr C, Fothergill A . Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 1997; 35(1):139-43. PMC: 229526. DOI: 10.1128/jcm.35.1.139-143.1997. View

14.

Galgiani J, Lewis M . In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997; 41(1):180-3. PMC: 163681. DOI: 10.1128/AAC.41.1.180. View

15.

Caillot D, Casasnovas O, Bernard A, Couaillier J, Durand C, Cuisenier B . Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997; 15(1):139-47. DOI: 10.1200/JCO.1997.15.1.139. View

16.

Pfaller M, Messer S, Jones R . Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1997; 41(2):233-5. PMC: 163694. DOI: 10.1128/AAC.41.2.233. View

17.

Oakley K, Moore C, Denning D . In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother. 1997; 41(5):1124-6. PMC: 163861. DOI: 10.1128/AAC.41.5.1124. View

18.

Oakley K, Morrissey G, Denning D . Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41(7):1504-7. PMC: 163948. DOI: 10.1128/AAC.41.7.1504. View

19.

Lutz J, Clemons K, Aristizabal B, Stevens D . Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother. 1997; 41(7):1558-61. PMC: 163958. DOI: 10.1128/AAC.41.7.1558. View

20.

Law D, Moore C, Denning D . Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother. 1997; 41(10):2310-1. PMC: 164118. DOI: 10.1128/AAC.41.10.2310. View